COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Bevacizumab vs Dacarbazine in Metastatic Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01705392
Recruitment Status : Terminated (Lack of financing of the study drug. Not sufficient financial support.)
First Posted : October 12, 2012
Last Update Posted : February 24, 2017
The Norwegian Melanoma Group
Norwegian Cancer Society
Information provided by (Responsible Party):
Haukeland University Hospital

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : February 20, 2017
Actual Study Completion Date : February 20, 2017